Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M88,443Revenue $M25,711Net Margin (%)7.8Z-Score2.6
Enterprise Value $M92,763EPS $2.0Operating Margin %11.8F-Score4
P/E(ttm))45.8Cash Flow Per Share $0Pre-tax Margin (%)9.2Higher ROA y-yN
Price/Book4.310-y EBITDA Growth Rate %10.2Quick Ratio0.9Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %-9.0Current Ratio1.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-23.9ROA % (ttm)3.5Higher Current Ratio y-yN
Dividend Yield %4.0Insider Buy (3m)0ROE % (ttm)8.8Less Shares Outstanding y-yN
Payout Ratio %174Shares Outstanding M1,263ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNGeorge Soros 2014-06-30 Buy 0.08%$62.45 - $81.09
($72.26)
$ 70.62-2%New holding, 150000 sh.150,000
AZNMario Gabelli 2014-06-30 Buy 0.02%$62.45 - $81.09
($72.26)
$ 70.62-2%New holding, 40400 sh.40,400
AZNCharles Brandes 2014-06-30 Reduce-0.78%$62.45 - $81.09
($72.26)
$ 70.62-2%Reduce -71.06%386,058
AZNJoel Greenblatt 2014-06-30 Sold Out -0.09%$62.45 - $81.09
($72.26)
$ 70.62-2%Sold Out0
AZNJohn Hussman 2014-03-31 Add0.96%$58.51 - $68.15
($64.29)
$ 70.6210%Add 714.29%228,000
AZNDavid Dreman 2014-03-31 Add0.14%$58.51 - $68.38
($64.41)
$ 70.6210%Add 26.61%135,439
AZNJoel Greenblatt 2014-03-31 Buy 0.09%$58.51 - $68.38
($64.41)
$ 70.6210%New holding, 95518 sh.95,518
AZNCharles Brandes 2014-03-31 Reduce-0.84%$58.51 - $68.15
($64.29)
$ 70.6210%Reduce -46.73%1,333,894
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 70.6230%Reduce -40.32%106,975
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 70.6230%Reduce -58.82%28,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 70.6241%Add 7.92%2,381,040
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 70.6241%Reduce -81.87%68,000
AZNJohn Hussman 2013-06-30 Reduce-1.02%$47.22 - $53.01
($50.92)
$ 70.6239%Reduce -59.76%375,000
AZNJoel Greenblatt 2013-06-30 Sold Out -0.24%$47.22 - $53.01
($50.92)
$ 70.6239%Sold Out0
AZNJohn Hussman 2013-03-31 Reduce-0.74%$44.67 - $50.06
($47.4)
$ 70.6249%Reduce -38.8%932,000
AZNCharles Brandes 2012-12-31 Buy 1.2%$44.34 - $48.9
($46.77)
$ 70.6251%New holding, 2188735 sh.2,188,735
AZNJohn Hussman 2012-12-31 Reduce-0.56%$44.34 - $48.9
($46.77)
$ 70.6251%Reduce -24.49%1,523,000
AZNDavid Dreman 2012-12-31 Reduce-0.2%$44.34 - $48.9
($46.77)
$ 70.6251%Reduce -52.4%152,504
AZNJoel Greenblatt 2012-12-31 Reduce-0.12%$44.34 - $48.9
($46.77)
$ 70.6251%Reduce -31.34%83,972
AZNJoel Greenblatt 2012-09-30 Add0.12%$44.91 - $48.35
($46.83)
$ 70.6251%Add 42.7%122,294
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AZN Mario Gabelli 2014-06-3040,40000.02New Buy
AZN George Soros 2014-06-30150,0000.010.08New Buy
AZN - CALLDaniel Loeb 2014-06-301,000,0000.080.91
AZN John Hussman 2014-06-30223,5000.021.3-1.97%
AZN David Dreman 2014-06-30117,8320.010.66-13%
AZN Charles Brandes 2014-06-30386,0580.030.35-71.06%
AZN Joel Greenblatt 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about azn:

      Articles On GuruFocus.com
      Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
      I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
      A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
      Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 
      Abbott Capturing Incremental Market Share Mar 18 2014 
      Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
      10 British Stocks to Consider Feb 20 2014 
      Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
      AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 


      More From Other Websites
      Nektar/AstraZeneca's Moventig a Step Closer to EU Approval Sep 29 2014
      Clovis Shares Higher on Improved Outlook for Lung Cancer Drug Sep 29 2014
      Cancer drug stocks on the move amid striking data Sep 29 2014
      7:50 am AstraZeneca updates on progress of oncology pipeline at ESMO 2014 congress Sep 29 2014
      GlaxoSmithKline plc Is Still A Better Pick Than AstraZeneca plc Sep 29 2014
      Bristol immune drug shows strong effect in melanoma study Sep 29 2014
      Bristol immune drug shows strong effect in melanoma study Sep 29 2014
      Merck drug extends immune system fight to stomach cancer Sep 28 2014
      No benefit from continued use of AstraZeneca's Iressa drug Sep 28 2014
      Bristol immunotherapy gets 6-month U.S. FDA review for melanoma Sep 26 2014
      EU agency backs AstraZeneca's MOVENTIG drug Sep 26 2014
      AstraZeneca says expanded use of lung cancer drug backed by EU agency Sep 26 2014
      AstraZeneca says expanded use of lung cancer drug backed by EU agency Sep 26 2014
      Why IGI Laboratories (IG) Stock Hit a One-Year High Today Sep 25 2014
      EU agency backs Almirall lung drug being bought by AstraZeneca Sep 25 2014
      3 Neil Woodford Plays On Ageing Populations: AstraZeneca plc, Smith & Nephew plc And Capita PLC Sep 25 2014
      TNT Express slumps; Rio Tinto climbs: Europe’s stock movers Sep 24 2014
      Stock Market News for September 24, 2014 Sep 24 2014
      Is AstraZeneca plc A Safe Dividend Investment? Sep 24 2014
      AstraZeneca suitor Pfizer eyes another target Sep 24 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK